The flu treatment Relenza looks unlikely to be made available on the National
Health Service in Britain. As 91av went to press, the National
Institute for Clinical Excellence was thought to have advised against releasing
the drug, which limits symptoms and hastens recovery. Richard Sykes, chairman of
Glaxo Wellcome, the drug’s maker, is incensed. Yet a company data sheet prepared
in August states that the drug has yet to be shown to work in chronically ill or
immunocompromised patients, who are most at risk from complications of the
flu.
More from 91av
Explore the latest news, articles and features
Popular articles
Trending 91av articles
1
Fully autonomous drones have killed human soldiers for the first time
2
Toy universe shows that time could be a quantum illusion
3
Understanding anorexia’s grip on the brain could unlock new therapies
4
What is a ‘normal’ memory slowdown, and when should I worry?
5
Hundreds of new moons are revealing our solar system's violent history
6
Wolves seen hunting European bison in rare camera-trap recording
7
Mysterious ‘cold blob’ in the Atlantic suggests the AMOC is weakening
8
El Niño has started and the weather could get weird
9
A nuclear war between India and Pakistan could destroy the ozone layer
10
Dramatic photo of ibis being guided to their winter homes wins award
